PHYTONADIONE
PHYTONADIONE is indicated for the treatment of Coagulation Disorder; Hemorrhagic Disease of the Newborn; Obstructive Jaundice; Biliary Fistula; Sprue; Ulcerative Colitis; Celiac Disease; Cystic Fibrosis.
Details
- Status
- Prescription
- First Approved
- 1976-03-01
- Routes
- ORAL, INJECTION
- Dosage Forms
- TABLET, INJECTABLE
Companies
PHYTONADIONE Approval History
What PHYTONADIONE Treats
8 indicationsPHYTONADIONE is approved for 8 conditions since its original approval in 1976. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Coagulation Disorder
- Hemorrhagic Disease of the Newborn
- Obstructive Jaundice
- Biliary Fistula
- Sprue
- Ulcerative Colitis
- Celiac Disease
- Cystic Fibrosis
PHYTONADIONE Boxed Warning
WARNING — INTRAVENOUS AND INTRAMUSCULAR USE Severe reactions, including fatalities, have occurred during and immediately after INTRAVENOUS injection of phytonadione, even when precautions have been taken to dilute the phytonadione and to avoid rapid infusion. Severe reactions, including fatalities, have also been reported following INTRAMUSCULAR administration. Typically these severe reactions have resembled hypersensitivity or anaphylaxis, including shock and cardiac and/or respiratory arrest. ...
WARNING — INTRAVENOUS AND INTRAMUSCULAR USE Severe reactions, including fatalities, have occurred during and immediately after INTRAVENOUS injection of phytonadione, even when precautions have been taken to dilute the phytonadione and to avoid rapid infusion. Severe reactions, including fatalities, have also been reported following INTRAMUSCULAR administration. Typically these severe reactions have resembled hypersensitivity or anaphylaxis, including shock and cardiac and/or respiratory arrest. Some patients have exhibited these severe reactions on receiving phytonadione for the first time. Therefore the INTRAVENOUS and INTRAMUSCULAR routes should be restricted to those situations where the subcutaneous route is not feasible and the serious risk involved is considered justified.
PHYTONADIONE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in PHYTONADIONE's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications PHYTONADIONE treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to PHYTONADIONE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PHYTONADIONE FDA Label Details
Indications & Usage
FDA Label (PDF)PHYTONADIONE is indicated for the treatment of Coagulation Disorder; Hemorrhagic Disease of the Newborn; Obstructive Jaundice; Biliary Fistula; Sprue; Ulcerative Colitis; Celiac Disease; Cystic Fibrosis.
WARNING — INTRAVENOUS AND INTRAMUSCULAR USE Severe reactions, including fatalities, have occurred during and immediately after INTRAVENOUS injection of phytonadione, even when precautions have been taken to dilute the phytonadione and to avoid rapid infusion. Severe reactions, including fatalities, ...
Looking for the branded version?
VITAMIN K1
Full clinical data, patents, trials, and competitive landscape for phytonadione.
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.